High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant

J. G. O'Leary, H. Kaneku, B. M. Susskind, L. W. Jennings, M. A. Neri, G. L. Davis, G. B. Klintmalm, P. I. Terasaki

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

In contrast to kidney transplantation where donor-specific anti-HLA antibodies (DSA) negatively impact graft survival, correlation of DSA with clinical outcomes in patients after orthotopic liver transplantation (OLT) has not been clearly established. We hypothesized that DSA are present in patients who develop chronic rejection after OLT. Prospectively collected serial serum samples on 39 primary OLT patients with biopsy-proven chronic rejection and 39 comparator patients were blinded and analyzed for DSA using LABScreen® single antigen beads test, where a 1000 mean fluorescence value was considered positive. In study patients, the median graft survival was 15 months, 74% received ≥ one retransplant, 20% remain alive and 87% had ≥ one episode of acute rejection. This is in contrast to comparator patients where 69% remain alive, and no patient needed retransplant or experienced rejection. Thirty-six chronic rejection patients (92%) and 24 (61%) comparator patients had DSA (p = 0.003). Chronic rejection versus comparator patients had higher mean fluorescence intensity (MFI) DSA. Although a further study with larger numbers of patients is needed to identify clinically significant thresholds, there is an association of high-MFI DSA with chronic rejection after OLT. Serial serum samples from 39 chronic rejection and 39 comparator liver transplant recipients show a strong association between donor-specific antibody and chronic rejection, and the effects of preformed donor class I specific antibody can be mitigated by antibody induction therapy. See editorial by Briggs and Adams on page 1767.

Original languageEnglish (US)
Pages (from-to)1868-1876
Number of pages9
JournalAmerican Journal of Transplantation
Volume11
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Graft Rejection
Anti-Idiotypic Antibodies
Fluorescence
Tissue Donors
Liver Transplantation
Graft Survival
Antibodies
Serum
Kidney Transplantation
Biopsy
Antigens

Keywords

  • Chronic allograft rejection
  • donor-specific antibodies
  • HLA antibodies
  • Liver Transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. / O'Leary, J. G.; Kaneku, H.; Susskind, B. M.; Jennings, L. W.; Neri, M. A.; Davis, G. L.; Klintmalm, G. B.; Terasaki, P. I.

In: American Journal of Transplantation, Vol. 11, No. 9, 01.09.2011, p. 1868-1876.

Research output: Contribution to journalArticle

O'Leary, J. G. ; Kaneku, H. ; Susskind, B. M. ; Jennings, L. W. ; Neri, M. A. ; Davis, G. L. ; Klintmalm, G. B. ; Terasaki, P. I. / High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. In: American Journal of Transplantation. 2011 ; Vol. 11, No. 9. pp. 1868-1876.
@article{edd2357c53d84ed9a250259f99732dc0,
title = "High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant",
abstract = "In contrast to kidney transplantation where donor-specific anti-HLA antibodies (DSA) negatively impact graft survival, correlation of DSA with clinical outcomes in patients after orthotopic liver transplantation (OLT) has not been clearly established. We hypothesized that DSA are present in patients who develop chronic rejection after OLT. Prospectively collected serial serum samples on 39 primary OLT patients with biopsy-proven chronic rejection and 39 comparator patients were blinded and analyzed for DSA using LABScreen{\circledR} single antigen beads test, where a 1000 mean fluorescence value was considered positive. In study patients, the median graft survival was 15 months, 74{\%} received ≥ one retransplant, 20{\%} remain alive and 87{\%} had ≥ one episode of acute rejection. This is in contrast to comparator patients where 69{\%} remain alive, and no patient needed retransplant or experienced rejection. Thirty-six chronic rejection patients (92{\%}) and 24 (61{\%}) comparator patients had DSA (p = 0.003). Chronic rejection versus comparator patients had higher mean fluorescence intensity (MFI) DSA. Although a further study with larger numbers of patients is needed to identify clinically significant thresholds, there is an association of high-MFI DSA with chronic rejection after OLT. Serial serum samples from 39 chronic rejection and 39 comparator liver transplant recipients show a strong association between donor-specific antibody and chronic rejection, and the effects of preformed donor class I specific antibody can be mitigated by antibody induction therapy. See editorial by Briggs and Adams on page 1767.",
keywords = "Chronic allograft rejection, donor-specific antibodies, HLA antibodies, Liver Transplantation",
author = "O'Leary, {J. G.} and H. Kaneku and Susskind, {B. M.} and Jennings, {L. W.} and Neri, {M. A.} and Davis, {G. L.} and Klintmalm, {G. B.} and Terasaki, {P. I.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1600-6143.2011.03593.x",
language = "English (US)",
volume = "11",
pages = "1868--1876",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant

AU - O'Leary, J. G.

AU - Kaneku, H.

AU - Susskind, B. M.

AU - Jennings, L. W.

AU - Neri, M. A.

AU - Davis, G. L.

AU - Klintmalm, G. B.

AU - Terasaki, P. I.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - In contrast to kidney transplantation where donor-specific anti-HLA antibodies (DSA) negatively impact graft survival, correlation of DSA with clinical outcomes in patients after orthotopic liver transplantation (OLT) has not been clearly established. We hypothesized that DSA are present in patients who develop chronic rejection after OLT. Prospectively collected serial serum samples on 39 primary OLT patients with biopsy-proven chronic rejection and 39 comparator patients were blinded and analyzed for DSA using LABScreen® single antigen beads test, where a 1000 mean fluorescence value was considered positive. In study patients, the median graft survival was 15 months, 74% received ≥ one retransplant, 20% remain alive and 87% had ≥ one episode of acute rejection. This is in contrast to comparator patients where 69% remain alive, and no patient needed retransplant or experienced rejection. Thirty-six chronic rejection patients (92%) and 24 (61%) comparator patients had DSA (p = 0.003). Chronic rejection versus comparator patients had higher mean fluorescence intensity (MFI) DSA. Although a further study with larger numbers of patients is needed to identify clinically significant thresholds, there is an association of high-MFI DSA with chronic rejection after OLT. Serial serum samples from 39 chronic rejection and 39 comparator liver transplant recipients show a strong association between donor-specific antibody and chronic rejection, and the effects of preformed donor class I specific antibody can be mitigated by antibody induction therapy. See editorial by Briggs and Adams on page 1767.

AB - In contrast to kidney transplantation where donor-specific anti-HLA antibodies (DSA) negatively impact graft survival, correlation of DSA with clinical outcomes in patients after orthotopic liver transplantation (OLT) has not been clearly established. We hypothesized that DSA are present in patients who develop chronic rejection after OLT. Prospectively collected serial serum samples on 39 primary OLT patients with biopsy-proven chronic rejection and 39 comparator patients were blinded and analyzed for DSA using LABScreen® single antigen beads test, where a 1000 mean fluorescence value was considered positive. In study patients, the median graft survival was 15 months, 74% received ≥ one retransplant, 20% remain alive and 87% had ≥ one episode of acute rejection. This is in contrast to comparator patients where 69% remain alive, and no patient needed retransplant or experienced rejection. Thirty-six chronic rejection patients (92%) and 24 (61%) comparator patients had DSA (p = 0.003). Chronic rejection versus comparator patients had higher mean fluorescence intensity (MFI) DSA. Although a further study with larger numbers of patients is needed to identify clinically significant thresholds, there is an association of high-MFI DSA with chronic rejection after OLT. Serial serum samples from 39 chronic rejection and 39 comparator liver transplant recipients show a strong association between donor-specific antibody and chronic rejection, and the effects of preformed donor class I specific antibody can be mitigated by antibody induction therapy. See editorial by Briggs and Adams on page 1767.

KW - Chronic allograft rejection

KW - donor-specific antibodies

KW - HLA antibodies

KW - Liver Transplantation

UR - http://www.scopus.com/inward/record.url?scp=80052261583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052261583&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2011.03593.x

DO - 10.1111/j.1600-6143.2011.03593.x

M3 - Article

VL - 11

SP - 1868

EP - 1876

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 9

ER -